Adam Keeney's Insider Trades & SAST Disclosures
Adam Keeney's most recent trade in Biogen Inc was a trade of 938 Restricted Stock Unit done . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Adam Keeney.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 938 | 939 | - | - | Restricted Stock Unit | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 938 | 2,838 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.93 per share. | 01 May 2025 | 454 | 2,384 (0%) | 0% | 120.9 | 54,902 | Common Stock |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 9,835 | 9,835 | - | - | Restricted Stock Unit | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,801 | 3,604 | - | - | Restricted Stock Unit | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,801 | 2,463 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 563 | 1,900 (0%) | 0% | 141.3 | 79,580 | Common Stock |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 938 | 1,877 | - | - | Restricted Stock Unit | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 938 | 938 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 216.13 per share. | 01 May 2024 | 276 | 662 (0%) | 0% | 216.1 | 59,652 | Common Stock |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 5,405 | 5,405 | - | - | Restricted Stock Unit | |
| Biogen Inc | Adam Keeney | Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 2,815 | 2,815 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges